Abstract |
The aim of this study was to determine the risk factors for high-frequency hearing loss in children treated with cisplatin. We scored off-treatment pure-tone audiograms from 153 children (age 6 months to 18 years) who had completed cisplatin therapy (40-200 mg/m(2)/cycle) for germ cell tumours, hepatoblastoma, neuroblastoma or osteosarcoma. The risk of developing bilateral moderate to severe high-frequency hearing loss was significantly related to the age at treatment (P<0.001), and individual and cumulative cisplatin dosages (both P<0.005). Logistic regression showed that children younger than 5 years were at a greater risk of sustaining cisplatin ototoxicity than children older than 15 years, controlling for individual and cumulative doses of cisplatin (Odds Ratio (OR)=21.17, 95% Confidence Interval (CI): 2.48-180.94). Age at treatment and the cumulative dose of cisplatin were the two most important risk factors in predicting moderate to severe high-frequency hearing loss in children treated with cisplatin.
|
Authors | Y Li, R B Womer, J H Silber |
Journal | European journal of cancer (Oxford, England : 1990)
(Eur J Cancer)
Vol. 40
Issue 16
Pg. 2445-51
(Nov 2004)
ISSN: 0959-8049 [Print] England |
PMID | 15519518
(Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antineoplastic Agents
- Cisplatin
|
Topics |
- Adolescent
- Age Factors
- Antineoplastic Agents
(adverse effects)
- Audiometry, Pure-Tone
- Child
- Child, Preschool
- Cisplatin
(adverse effects)
- Confidence Intervals
- Dose-Response Relationship, Drug
- Female
- Hearing Loss, High-Frequency
(chemically induced)
- Humans
- Infant
- Logistic Models
- Male
- Predictive Value of Tests
- Risk Assessment
- Risk Factors
|